open access

Vol 7, No 3 (2006): Practical Diabetology
Original articles (submitted)
Published online: 2006-05-22
Get Citation

The role of glucagon-like peptide 1-receptor gene in type 2 diabetes

Jakub Frey, Maciej T. Małecki, Jan Skupień, Leszek Drabik, Elżbieta Hajto, Kazimierz Rajda, Paweł P. Wołkow, Ryszard Korbut, Jacek Sieradzki
Diabetologia Praktyczna 2006;7(3):150-154.

open access

Vol 7, No 3 (2006): Practical Diabetology
Original articles (submitted)
Published online: 2006-05-22

Abstract

INTRODUCTION. The aim of the study was to search for the association between Gly168Ser and Leu260Phe amino acid variants of the glucagon-like peptide 1 receptor gene and type 2 diabetes in a Polish population.
METHODS. 462 patients with type 2 diabetes and 428 healthy volunteers were genotyped by restriction fragments length polymorphism method after amplification of examined genome fragment by polymerase chain reaction technique. The digestion products were separated and visualized by electrophoresis on agarose gel containing ethidium bromide. Statistical analysis involved chi-square test for genotype-phenotype association and logistic regression for association of phenotype with haplotypes.
RESULTS. Ser/Ser homozygotes frequency in diabetic patients group was significantly higher than in control group (15.7% vs. 9.8%, p = 0,03). Odds ratio of having type 2 diabetes in Ser/Ser carriers group versus other genotype carriers showed almost two fold risk increase associated with this genotype. Polymorphism in 260 amino acid position and haplotypes of the analyzed polymorphisms were not associated with type 2 diabetes.
CONCLUSIONS. The results of the study suggest that polymorphism Gly168Ser may be potentially a risk factor of the type 2 diabetes in Polish population. This observation should be evaluated in other ethnic groups.

Abstract

INTRODUCTION. The aim of the study was to search for the association between Gly168Ser and Leu260Phe amino acid variants of the glucagon-like peptide 1 receptor gene and type 2 diabetes in a Polish population.
METHODS. 462 patients with type 2 diabetes and 428 healthy volunteers were genotyped by restriction fragments length polymorphism method after amplification of examined genome fragment by polymerase chain reaction technique. The digestion products were separated and visualized by electrophoresis on agarose gel containing ethidium bromide. Statistical analysis involved chi-square test for genotype-phenotype association and logistic regression for association of phenotype with haplotypes.
RESULTS. Ser/Ser homozygotes frequency in diabetic patients group was significantly higher than in control group (15.7% vs. 9.8%, p = 0,03). Odds ratio of having type 2 diabetes in Ser/Ser carriers group versus other genotype carriers showed almost two fold risk increase associated with this genotype. Polymorphism in 260 amino acid position and haplotypes of the analyzed polymorphisms were not associated with type 2 diabetes.
CONCLUSIONS. The results of the study suggest that polymorphism Gly168Ser may be potentially a risk factor of the type 2 diabetes in Polish population. This observation should be evaluated in other ethnic groups.
Get Citation

Keywords

type 2 diabetes mellitus; GLP-1R; genetic background of diabetes

About this article
Title

The role of glucagon-like peptide 1-receptor gene in type 2 diabetes

Journal

Clinical Diabetology

Issue

Vol 7, No 3 (2006): Practical Diabetology

Pages

150-154

Published online

2006-05-22

Bibliographic record

Diabetologia Praktyczna 2006;7(3):150-154.

Keywords

type 2 diabetes mellitus
GLP-1R
genetic background of diabetes

Authors

Jakub Frey
Maciej T. Małecki
Jan Skupień
Leszek Drabik
Elżbieta Hajto
Kazimierz Rajda
Paweł P. Wołkow
Ryszard Korbut
Jacek Sieradzki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl